Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease

International Psychogeriatrics

Volumn 14, Issue 4, 2002, Pages 389-404

  Gauthier, Serge ^a   Feldman, Howard ^b   Hecker, Jane ^c   Vellas, Bruno ^d   Ames, David ^e   Subbiah, Ponni ^f   Whalen, Edward ^f   Emir, Birol ^f   Albarede P J ^g   Ancill, R J ^h   Atallah, S ⁱ   Bailey, P ^ai   Black, S E ^j   Borrie, M J ^k   Boundy, K ^l   Clarnette, R ^m   Cohen, S ⁿ   Darby, D G ^o   Ewer, M ^p   Farcnik, K ^q   Helme, R D ^r   Hogan, D ^s   Kertesz, A ^t   Masters, C ^u   Maupetit, J ^v   McCracken, P ^w   Mohr, E ^x   Molloy, D W ^y   Mordasini, M ^z   Moscovitch, A ^aa   Patterson, C ^y   Pillay, N ^ab,ac   Rabheru, K ^ad   Rajput, A ^ae   Rousseau, F ^af   Tessier, D ^ag   Veloso, F ^ah   Willmer, J ^ai   more..

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c REPATRIATION GENERAL HOSPITAL   (Australia)

^d UNIVERSITÉ DE TOULOUSE   (France)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f PFIZER INC   (United States)

^g Serv Univ Psychiat l'Enfant l'A   (France)

^h St Vincent's Hospital   (Canada)

ⁱ Résidence de Montvenoux   (France)

^j SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^k PARKWOOD HOSPITAL   (Canada)

^l QUEEN ELIZABETH HOSPITAL   (Australia)

^m Osborne Park Hospital   (Australia)

ⁿ Seniors' Health Centre   (Australia)

^o AUSTIN HEALTH   (Australia)

^p Adelaide Clinic   (Australia)

^q TORONTO WESTERN HOSPITAL   (Canada)

^r NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^s Health Sciences Centre Calgary   (Canada)

^t ST JOSEPH S HEALTH CENTRE   (Canada)

^u FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^v CHG Hôpital Garderose   (France)

^w GLENROSE REHABILITATION HOSPITAL   (Canada)

^x Pacific Neuroscience Institute   (Canada)

^y HAMILTON HEALTH SCIENCES   (Canada)

^z Centre Hospitalier de Ravenel   (France)

^aa Canadian Sleep Institute   (Canada)

^ab M C Neurology Clinical Trials   (Canada)

^ac Peter Lougheed Hospital   (Canada)

^ad London Psychiatric Hospital   (Canada)

^ae ROYAL UNIVERSITY HOSPITAL   (Canada)

^af Clinique Roy Rousseau   (Canada)

^ag UNIVERSITY INSTITUTE OF GERIATRICS OF SHERBROOKE   (Canada)

^ah Saskatchewan Health Authority   (Canada)

^ai Pasqua Hospital ^*

more..

Author keywords

Alzheimer's disease; Behavior; Donepezil; Neuropsychiatric symptoms

Indexed keywords

ANTIDEPRESSANT AGENT; BROMAZEPAM; DIAZEPAM; DONEPEZIL; HALOPERIDOL; LORAZEPAM; LOXAPINE; OXAZEPAM; PAROXETINE; PLACEBO; PSYCHOTROPIC AGENT; RISPERIDONE; SERTRALINE; TEMAZEPAM; ZOLPIDEM; ZOPICLONE;

AGED; AGITATION; ALZHEIMER DISEASE; ANXIETY; APATHY; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DYSPHORIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LOCOMOTION; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; ANXIETY; AROUSAL; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; MALE; MENTAL STATUS SCHEDULE; NOOTROPIC AGENTS; PIPERIDINES; SOCIAL BEHAVIOR DISORDERS; TREATMENT OUTCOME;

EID: 0036942425     PISSN: 10416102     EISSN: None     Source Type: Journal    
DOI: 10.1017/S104161020200858X     Document Type: Article

References (41)

1. Aarsland, D., Cummings, J. L., Yener, G., & Miller, B. (1996). Relationship of aggressive behavior to other neuropsychiatric symptoms in patients with Alzheimer's disease. American Journal of Psychiatry, 153, 243-247.
2. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
3. Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science, 217, 408-414.
4. Burns, A., Rossor, M., Hecker, J., Gauthier, S., Petit, H., et al., and the International Donepezil Study Group. (1999). The effects of donepezil in Alzheimer's disease - Results from a multinational trial. Dementia and Geriatric Cognitive Disorders, 10, 237-244.
5. Coen, R. F., Swanwick, G. R. J., O'Boyle, C. A., & Coakley, D. (1997). Behaviour disturbance and other predictors of carer burden in Alzheimer's disease. International Journal of Geriatric Psychiatry, 12, 331-336.
6. Cohen-Mansfield, J., & Marx, M. S. (1988). Relationship between depression and agitation in nursing home residents. Comprehensive Gerontology [B], 2, 141-146.
7. Craig, A. H., Cummings, J. L., Fairbanks, L., Itti, L., Miller, B. L., et al. (1996). Cerebral blood flow correlates of apathy in Alzheimer disease. Archives of Neurology, 53, 1116-1120.
8. Cummings, J. L., & Back, C. (1998). The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. American Journal of Geriatric Psychiatry, 6(Suppl. 1), S64-S78.
9. Cummings, J. L., & Kaufer, D. (1996). Neuropsychiatric aspects of Alzheimer's disease. The cholinergic hypothesis revisited. Neurology, 47, 876-883.
10. Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., et al. (1994). The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology, 44, 2308-2314.
11. Devanand, D. P., Jacobs, D. M., Tang, M. X., Del Castillo-Castaneda, C., Sano, M., et al. (1997). The course of psychopathologic features in mild to moderate Alzheimer disease. Archives of General Psychiatry, 54, 257-263.
12. Duffy, J. D. (1997). The neural substrates of motivation. Psychiatric Annals, 27, 24-29.
13. Fahn, S., & Elton, R. (1987). Unified Parkinson's Disease Rating Scale. In S. Fahn, C. Marsden, M. Goldstein, et al. (Eds.), Recent developments in Parkinson's disease (Vol. 12, pp. 153-163). Florham Park, NJ: MacMillan Healthcare.
14. Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Subbiah, P., et al. (2001). A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology, 57, 613-620.
15. Frisoni, G. B., Rozzini, L., Gozzetti, A., Binetti, G., Zanetti, O., et al. (1999). Behavioral syndromes in Alzheimer's disease: Description and correlates. Dementia and Geriatric Cognitive Disorders, 10, 130-138.
16. Haupt, M., & Kurz, A. (1993). Predictors of nursing home placement in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry, 8, 741-746.
17. Haupt, M., Kurz, A., & Jänner, M. (2000). A 2-year follow-up of behavioural and psychological symptoms in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 11, 147-152.
18. Hope, T., Keene, J., Gedling, K., Fairburn, C. G., & Jacoby, R. (1998). Prediction of institutionalization for people with dementia living at home with a carer. International Journal of Geriatric Psychiatry, 13, 682-690.
19. Kaufer, D. I., Catt, K., Pollock, B. G., Lopez, O. M., & DeKosky, S. T. (1998). Donepezil in Alzheimer's disease: Relative cognitive and neuropsychiatric responses and impact on caregiver distress. Neurology, 50, A89.
20. Kaufer, D. I., Cummings, J. L., & Christine, D. (1996). Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study. Journal of Geriatric Psychiatry and Neurology, 9, 1-6.
21. Keene, J., Hope, T., Fairburn, C. G., Jacoby, R., Gedling, K., et al. (1999). Natural history of aggressive behaviour in dementia. International Journal of Geriatric Psychiatry, 14, 541-548.
22. Kuzis, G., Sabe, L., Tiberti, C., Dorrego, F., & Starkstein, S. E. (1999). Neuropsychological correlates of apathy and depression in patients with dementia. Neurology, 52, 1403-1407.
23. Lanctôt, K. L., & Herrmann, N. (2000). Donepezil for behavioural disorders associated with Lewy bodies: A case series. International Journal of Geriatric Psychiatry, 15, 338-345.
24. Marin, R. S. (1996). Apathy: Concept, syndrome, neural mechanisms, and treatment. Seminars in Clinical Neuropsychiatry, 1,304-314.
25. McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., et al. (2000). Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. Lancet, 356, 2031-2036.
26. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., et al. (1984). Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939-944.
27. Mega, M. S., Cummings, J. L., Fiorello, T., & Gornbein, J. (1996). The spectrum of behavioral changes in Alzheimer's disease. Neurology, 46, 130-135.
28. Mega, M. S., Masterman, D. M., O'Connor, S. M., Barclay, T. R., & Cummings, J. L. (1999). The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Archives of Neurology, 56, 1388-1393.
29. Mohs, R. C., Doody, R. S., Morris, J. C., leni, J. R., Rogers, S. L., et al. (2001). A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology, 57, 481-488.
30. Molloy, D. W., Alemayehu, E., & Roberts, R. (1991). Reliability of a standardized Mini-Mental State Examination compared with the traditional Mini-Mental State Examination. American Journal of Psychiatry, 148, 102-105.
31. Morris, J. C., Cyrus, P. A., Orazem, J., Mas, J., Bieber, F., et al. (1998). Metrifonate benefits cognitive, behavioral and global function in patients with Alzheimer's disease. Neurology, 50, 1222-1230.
32. Murman, D. L., Chen, Q., Powell, M. C., Colenda, C. C., & Lansing, E. (2001). The incremental costs associated with behavioral symptoms in Alzheimer's disease. Neurology, 56(Suppl. 3), A160-A161.
33. Perry, E. K., Kerwin, J., Perry, R. H., Irving, D., Blessed, G., et al. (1990). Cerebral cholinergic activity is related to the incidence of visual hallucinations in senile dementia of Lewy body type. Dementia, 1,2-4.
34. Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., & Friedhoff, L. T. (1998). A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology, 50, 136-145.
35. Sano, M. C., Berg, J. D., Thomas, R. G., Schneider, L. S., Aisen, P. S., et al. (2001). Incidence and persistence of psychosis in Alzheimer's disease. Neurology, 56(Suppl. 3), A179.
36. Sclan, S. G., & Reisberg, B. (1992). Functional assessment staging (FAST) in Alzheimer's disease: Reliability, validity, and ordinality. International Psychogeriatrics, 44, 55-69.
37. Sultzer, D. L., Mahler, M. E., Mandelkern, M. A., Cummings, J. L., Van Gorp, W. G., et al. (1995). The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences, 7, 476-484.
38. Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P., Lilienfeld, S., et al. (2000). A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology, 54, 2269-2276.
39. Teri, L. (1997). Behavior and caregiver burden: Behavioral problems in patients with Alzheimer's disease and its association with caregiver distress. Alzheimer Disease and Associated Disorders, 11(Suppl. 4), S35-S38.
40. Winblad, B., Engedal, K., Soininen, H., Verhey, F., Waldemar, G., et al., and the Donepezil Nordic Study Group. (2001). A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology, 57, 489-495.
41. World Medical Association. (1997). Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Journal of the American Medical Association, 277, 925-926.